Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romidepsin in RAI-Refractory Metastatic Thyroid Cancer
NCT00098813Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2004
- Primary completion
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of romidepsin in thyroid carcinoma (TC), sponsored by National Cancer Institute. Primary endpoints: Tumor Major Response Rate (Including Stable Disease) as Measured by RECIST Criteria at 8 weeks and Safety and Tolerability. Started Oct 2004; status: completed.
02
Drugs
romidepsin
03
Conditions
thyroid carcinoma (TC)
Beyond the preview
Go deeper on NCT00098813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00098813.